Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05386108
What this trial is testing

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Who this might be right for
Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more
Stemline Therapeutics, Inc. 73
Testing effectiveness (Phase 2)Looking for participantsNCT05181033
What this trial is testing

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
National University Hospital, Singapore 120
Large-scale testing (Phase 3)Study completedNCT02297438
What this trial is testing

Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Who this might be right for
Breast Neoplasms
Pfizer 340
Large-scale testing (Phase 3)Not Yet RecruitingNCT06929325
What this trial is testing

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Who this might be right for
HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 312
Early research (Phase 1)Study completedNCT03219268
What this trial is testing

MGD013 in Patients With Unresectable or Metastatic Neoplasms

Who this might be right for
Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more
MacroGenics 277
Testing effectiveness (Phase 2)UnknownNCT03933982
What this trial is testing

Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast CancerBrain Metastases
Chinese Academy of Medical Sciences 30
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Study completedNCT01963481
What this trial is testing

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Who this might be right for
Metastatic Beast Cancer
NYU Langone Health 23
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)Active Not RecruitingNCT02738866
What this trial is testing

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Who this might be right for
Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Large-scale testing (Phase 3)Study completedNCT01610284
What this trial is testing

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,147
Early research (Phase 1)Looking for participantsNCT07081555
What this trial is testing

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 + Breast Cancer
Affibody 21
Not applicableUnknownNCT05560308
What this trial is testing

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Who this might be right for
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Tianjin Medical University Cancer Institute and Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT01161368
What this trial is testing

A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Central European Cooperative Oncology Group 9
Early research (Phase 1)Study completedNCT04134884
What this trial is testing

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerHormone Receptor Positive Tumor
Kathy Miller 34
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Next Page